Adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer, Hormone receptor positive locally advanced breast cancer in postmenopausal women, Hormone receptor positive metastatic breast cancer in postmenopausal women, Hormone receptor unknown locally advanced breast cancer in postmenopausal women, Hormone receptor unknown metastatic breast cancer in postmenopausal women, Advanced breast cancer in postmenopausal women
Adult: 1 mg once daily. Recommended treatment duration: 5 years for adjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer. For the treatment of advanced breast cancer, efficacy has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.
|CrCl (ml/min)||Dosage Recommendation|
Special Populations: Pharmacogenomics: Anastrozole is a selective nonsteroidal aromatase inhibitor. Aromatase enzyme is encoded by CYP19 gene that is responsible for the final step in the conversion of androgen and oestrogens. Oestrogen acts as a growth factor for hormone-dependent breast cancer cells. Genotyping for CYP19 rs4646 gene polymorphism may play an important role in breast cancer survival. In a study conducted on 406 Chinese women with Stage I-II and operable Stage III breast cancer, the association between CYP19 rs4646 genotypes and disease-free survival (DFS) was evaluated. The study shows that polymorphism is related to DFS in early breast cancer and the prognosis may depend on the menopause status of the patient. CYP19 rs4646 polymorphism carrier of AA allele Patient may have increased treatment efficacy in pre-menopausal women and decreased treatment efficacy in postmenopausal women. CYP19 rs4646 polymorphism carrier of AC or CC allele Patient may have decreased treatment efficacy in pre-menopausal women and increased treatment efficacy in postmenopausal women. However, the findings are novel, and if confirmed, rs4646 genotyping may be a potential tool in the management of breast cancer.